Saturday 17 October 2026
Export CADL’s income statement to Excel — free account
Candel Therapeutics, Inc.
CADL Healthcare Biotechnology
Candel Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $125,000.00. In the quarter to June 2026, EPS fell 477.8%, free cash flow fell 93.4% and total debt rose 525.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.19
0.72
−8.08%
Follow CADL
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Piotroski F-Score |
— | — | — | 3 | 1 | — | — | — |
Altman Z-Score |
— | — | — | 2.39 | (1.20) | — | — | — |
P/S ratio |
— | 661.64 | 661.64 | 1,180.70 | 408.14 | — | — | — |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | 10.56 | (1.37) | 3.67 | 0.11 | — | — | — |
P/Operating CF |
— | (18.40) | (18.40) | (28.18) | (7.41) | — | — | — |
P/B ratio |
— | 0.00 | 0.00 | 2.30 | 1.07 | — | — | — |
Price to Tangible BV |
— | 0.00 | 0.00 | 2.30 | 1.07 | — | — | — |
EV/Sales |
— | 473.49 | 473.49 | 527.76 | 18.19 | — | — | — |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
EV/Operating CF |
— | (3.91) | (3.91) | (2.97) | (0.07) | — | — | — |
EV/FCF |
— | (3.43) | (3.43) | (2.74) | (0.07) | — | — | — |
Quick Ratio |
— | 31.96 | 7.44 | 15.41 | 12.48 | 2.50 | 2.74 | 13.31 |
Current Ratio |
— | 32.06 | 7.46 | 15.84 | 12.81 | 2.59 | 2.77 | 13.49 |
Net Debt/EBITDA |
— | 4.96 | 2.49 | 3.22 | 1.44 | 0.38 | 2.78 | 1.53 |
Debt/Assets |
0.00% | 0.92% | 2.47% | 0.63% | 27.43% | 51.64% | 11.70% | 37.65% |
Debt/Equity |
— | 0.01 | (0.04) | 0.01 | 0.45 | 1.67 | 0.19 | 0.91 |
Asset Turnover |
— | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.63 | 0.51 | 0.62 | 1.67 | 0.90 | 0.49 | 1.00 |
Capex/Depreciation |
— | 0.00 | (16.22) | (7.91) | (1.67) | (0.29) | (0.02) | (0.66) |
Interest Coverage |
— | (16.89) | (124.41) | — | (20.33) | (14.79) | (15.97) | (22.78) |
| — | 52.15% | 111.90% | (178.06%) | (33.61%) | (125.50%) | (139.56%) | (64.58%) | |
| — | (35.90%) | (42.00%) | (56.67%) | (22.52%) | (63.82%) | (74.53%) | (32.91%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (18.63%) | (53.22%) | (43.30%) | (26.56%) | (146.94%) | (80.59%) | (33.48%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
— | 5,251.20% | 7,003.20% | 12,142.40% | 16,629.60% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 2,044.00% | 4,144.80% | 8,538.40% | 11,248.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 1,685.60% | 2,370.40% | 1,845.60% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | (0.60) | (0.60) | 0.41 | 0.82 | — | — | — |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Earnings Yield |
— | (33.03%) | (33.03%) | (31.64%) | (36.72%) | — | — | — |
Free Cash Flow Yield |
— | (20.87%) | (20.87%) | (16.30%) | (64.13%) | — | — | — |
Revenue per Share |
— | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.18) | (0.78) | (1.18) | (1.09) | (1.18) | (0.85) | (0.72) |
Capex per Share |
— | 0.00 | (0.13) | (0.10) | (0.04) | (0.01) | 0.00 | (0.01) |
Free Cash Flow per Share |
— | (0.18) | (0.91) | (1.27) | (1.13) | (1.19) | (0.85) | (0.73) |
Cash per Share |
— | 1.55 | 3.02 | 4.38 | 2.43 | 1.22 | 3.24 | 2.26 |
Shareholders Equity per Share |
— | 1.41 | (2.03) | 3.40 | 1.66 | 0.44 | 2.09 | 0.98 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 1.41 | (2.03) | 3.40 | 1.66 | 0.44 | 2.09 | 0.98 |
Free Cash Flow |
— | (5.18) | (10.55) | (24.05) | (32.72) | (34.52) | (27.04) | (38.87) |
Working Capital |
— | 43.80 | 30.43 | 79.58 | 66.33 | 22.61 | 66.28 | 112.39 |
Capital Expenditures |
— | (0.16) | (1.48) | (1.83) | (1.30) | (0.28) | (0.02) | (0.56) |
Net Current Asset Value |
— | 40.33 | (26.70) | 59.88 | 41.97 | 8.34 | 63.27 | 48.12 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Capex to Sales |
— | 0.00 | 11.81 | 14.68 | 10.38 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.10 | 0.03 | 0.06 | 0.18 | 0.30 | 0.45 | 0.51 |
Cash ROIC |
— | (5.99%) | (84.80%) | (16.32%) | (23.52%) | (49.72%) | (14.90%) | (17.77%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — |
Average Payables |
— | 0.57 | 0.57 | 1.26 | 0.99 | 0.40 | 0.33 | 0.68 |
Average Assets |
— | 22.95 | 42.09 | 63.74 | 83.45 | 59.45 | 74.03 | 116.03 |
Average Common Equity |
— | (15.80) | (15.80) | 20.29 | 55.93 | 30.23 | 39.54 | 59.12 |
Columns are period end dates